13 results on '"QIANG JIA"'
Search Results
2. Thyroid Hormone Changes in the Northern Area of Tianjin during the COVID-19 Pandemic.
- Author
-
Weiwei D, Bei W, Hong W, Cailan W, Hailin S, Donghong X, Xiaolai W, Zhaohu H, Shijun L, Jian T, and Qiang J
- Abstract
Purpose: This study aimed to determine whether and how stress-induced thyroid hormone changes occur during the COVID-19 pandemic in the northern area of Tianjin., Methods: This study comprised two groups of study subjects in Tianjin: before (2019) and during (2020) the COVID-19 outbreak. Subjects were included if they had FT3, FT4, and TSH concentrations and thyroid TPOAb or TgAb information available. People who were pregnant, were lactating, or had mental illness were excluded. We used propensity score matching to form a cohort in which patients had similar baseline characteristics, and their anxiety level was measured by the Hamilton Anxiety Rating Scale (HAMA)., Results: Among the 1395 eligible people, 224 in Group A and 224 in Group B had similar propensity scores and were included in the analyses. The detection rate of abnormal thyroid function was decreased in pandemic Group B (69.2% vs. 93.3%, χ
2 = 42.725, p < 0.01), especially for hypothyroidism (14.29% vs. 35.71%, χ2 = 27.429, p < 0.01) and isolated thyroid-related antibodies (25.89% vs. 38.39%, χ2 = 8.023, p < 0.01). The level of FT4 ( z = -2.821, p < 0.01) and HAMA score (7.63 ± 2.07 vs. 5.40 ± 1.65, t = 16.873, p < 0.01) went up in Group B; however, TSH ( z = -5.238, p < 0.01), FT3 ( z = -3.089, p =0.002), TgAb ( z = -11.814, p < 0.01), and TPOAb ( z = -9.299, p < 0.01) were lower, and HAMA was positive with FT3 ( r = 0.208, p < 0.01) and FT4 ( r = 0.247, p < 0.01)., Conclusion: People in the northern area of Tianjin during the COVID-19 outbreak were at an increased risk of higher FT4, lower FT3, and lower TSH. The HAMA scores increased in emergency situations and were positively correlated with the levels of FT3 and FT4., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2022 Dong Weiwei et al.)- Published
- 2022
- Full Text
- View/download PDF
3. [Effect of walking mode on three-dimensional gait and EMG signals of human lower limbs].
- Author
-
Liang AD, Qiang JH, Ma Q, Niu XD, Zhang Y, and Chi AP
- Subjects
- Biomechanical Phenomena, Electromyography, Humans, Lower Extremity, Muscle, Skeletal, Gait, Walking
- Published
- 2020
- Full Text
- View/download PDF
4. Identification of key active constituents of Buchang Naoxintong capsules with therapeutic effects against ischemic stroke by using an integrative pharmacology-based approach.
- Author
-
Haiyu X, Yang S, Yanqiong Z, Qiang J, Defeng L, Yi Z, Feng L, and Hongjun Y
- Subjects
- Animals, Biological Availability, Biotransformation, Capsules, Chromatography, Liquid, Disease Models, Animal, Humans, Mass Spectrometry, Medicine, Chinese Traditional, Mice, Molecular Structure, Protein Interaction Mapping methods, Protein Interaction Maps, Rats, Reproducibility of Results, Stroke drug therapy, Workflow, Chemistry, Pharmaceutical methods, Drugs, Chinese Herbal chemistry, Drugs, Chinese Herbal pharmacology
- Abstract
Integrative pharmacology has been used to identify the key active constituents (KACs) of Buchang Naoxintong capsules (BNCs), a traditional Chinese medical preparation; this approach involves the evaluation of the content profiles and drug-like properties of the BNC constituents and development of an ingredient-target network. In this study, we used a sensitive analytical method to simultaneously identify and quantify 16 constituents of BNCs. Metabolism of these constituents by gut microbiota and human oral bioavailability were predicted using an in silico approach, followed by construction of networks to analyze the interactions between BNC constituents, their molecular targets, and proteins known to be the molecular targets for Food and Drug Administration-approved colitis medication. Finally, an animal model of ischemic stroke was used to verify the therapeutic effects of the KACs of BNCs. Amygdalin and paeoniflorin were identified as the KACs because they were the 2 most abundant BNC constituents, having appropriate drug-like properties, and produced therapeutic effects against cerebral ischemia. Amygdalin produced an anti-cerebral ischemia effect, likely by interacting with the glucocorticoid receptor (NR3C1) and serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINC1). These results form the basis for conducting studies to identify KACs in traditional medicinal preparations; such studies might improve quality control and allow the in vivo evaluation of synergistic interactions between the complex mixtures of compounds.
- Published
- 2016
- Full Text
- View/download PDF
5. Optimization of spatial acquisition systems for low-light-level robustness in space optical communications.
- Author
-
Bai S, Qiang J, Zhang L, and Wang J
- Abstract
The channel establishment in space optical communications relies on the Acquisition, Tracking, and Pointing (ATP) systems to initially acquire and then stably track the beacon beam. However, insufficient optical power may lead to unstable acquisition or even acquisition failure. In this Letter, we describe the mechanisms causing the instability, and then propose an approach to constrain the acquisition velocity. The approach is based on velocity prediction obtained from the light spot centroids and angle measurement data. Theoretical and experimental results show that the acceptable minimum optical power for acquisition decreases by 5.5 dB after optimization, which effectively enhances the acquisition system's robustness under low-light-level conditions. This approach improves the adaptability of satellite-ground optical communications and also has practical value for deep-space optical communications.
- Published
- 2015
- Full Text
- View/download PDF
6. Predictive filtering-based fast reacquisition approach for space-borne acquisition, tracking, and pointing systems.
- Author
-
Bai S, Wang J, Qiang J, Zhang L, and Wang J
- Abstract
We propose a novel approach for recapturing targets as quickly as possible after the space-borne ATP (Acquisition, Tracking, and Pointing) system target loss in free-space laser communication. The approach uses past angular information to predict the target trajectory. An optimized finite memory filter is designed as the prediction algorithm. To obtain optimal prediction performance, the designed filter determines the filter parameters of different curve parts during offline training, and the parameters are adjusted according to the curve characteristics during predictive filtering. Simulation results indicate prediction accuracy above 0.1 degrees within 5 seconds. An experimental system was constructed in the lab to simulate the reacquisition process using a dynamic target and a real ATP system. Experimental results show that, compared with the classical orbit prediction method, this approach can effectively yield shorter acquisition times.
- Published
- 2014
- Full Text
- View/download PDF
7. A novel baculovirus vector shows efficient gene delivery of modified porcine reproductive and respiratory syndrome virus antigens and elicits specific immune response.
- Author
-
Karuppannan AK, Qiang J, Chang CC, and Kwang J
- Subjects
- Animals, Antigens, Baculoviridae genetics, Cell Line, Drug Carriers administration & dosage, Female, Gene Expression, Genes, Insecta, Mice, Mice, Inbred BALB C, Porcine respiratory and reproductive syndrome virus genetics, Promoter Regions, Genetic, Transduction, Genetic, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Viral Envelope Proteins genetics, Viral Vaccines administration & dosage, Viral Vaccines genetics, White spot syndrome virus 1 genetics, Antibodies, Neutralizing blood, Antibodies, Viral blood, Porcine respiratory and reproductive syndrome virus immunology, Viral Envelope Proteins immunology, Viral Vaccines immunology
- Abstract
Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating epizootic of porcine species. Current vaccines are inadequate to control the disease burden and outbreaks in the field. We report a novel baculovirus vaccine vector with White spot syndrome virus immediate early 1 shuttle promoter, with strong activity in both insect cells and mammalian cells, for immunization against PRRSV. The insect cell cultured baculovirus vector produces PRRSV envelope glycoproteins ORF2a, ORF3, ORF4 and ORF5, which are similar to the antigens in the infectious PRRS virion, and these antigens are stably incorporated on the surface of the baculovirus. Further, the baculovirus vector efficiently transduces these antigens in cells of porcine origin, thereby simulating a live infection. The baculovirus vectored PRRSV antigens, upon inoculation in mice, elicits robust neutralizing antibodies against the infective PRRS virus. Further, the experiments indicate that hitherto under emphasized ORF2a and ORF4 are important target antigens for neutralizing PRRSV infectivity., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
8. Natural compounds inhibiting the replication of Porcine reproductive and respiratory syndrome virus.
- Author
-
Karuppannan AK, Wu KX, Qiang J, Chu JJ, and Kwang J
- Subjects
- Animals, Antiviral Agents isolation & purification, Biological Products isolation & purification, Cell Line, Haplorhini, Porcine respiratory and reproductive syndrome virus physiology, Antiviral Agents pharmacology, Biological Products pharmacology, Porcine respiratory and reproductive syndrome virus drug effects, Virus Replication drug effects
- Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically important pathogenic virus in the swine production. Current vaccines against PRRSV do not induce sterile immunity and the virus evolves at a rapid rate with frequent appearances of new strains. In this study, we screened a library of 502 highly purified natural product compounds to identify specific inhibitors of PRRSV replication cycle. Our observations showed that many of the inhibitory compounds identified have activity on the cellular ion transport mechanisms. We identified for the first time, four compounds which inhibit the PRRSV replication cycle at micro molar concentration or less, namely, 12-deoxyphorbol 13-phenylacetate 20-acetate, ouabain, bufalin and valinomycin. Further, we have identified 15 other compounds which can inhibit the PRRSV replication at the concentration of 8μM. This study provides a basis for further development of pharmacological agents to inhibit PRRSV replication., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
9. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.
- Author
-
Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, and Kwang J
- Subjects
- Adjuvants, Immunologic administration & dosage, Animals, Cells, Cultured, Female, Hemagglutinin Glycoproteins, Influenza Virus administration & dosage, Hemagglutinin Glycoproteins, Influenza Virus genetics, Humans, Immunization, Influenza Vaccines genetics, Influenza Vaccines immunology, Influenza, Human immunology, Influenza, Human prevention & control, Injections, Subcutaneous, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Pandemics, Recombination, Genetic, Spodoptera, Vaccines, Inactivated genetics, Vaccines, Inactivated immunology, Antibodies, Viral blood, Baculoviridae genetics, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines administration & dosage, Vaccines, Inactivated administration & dosage
- Abstract
The protective immunity of baculovirus displaying influenza virus hemagglutinin (BacHA) against influenza 2009 H1N1 virus infection in a murine model was investigated. The results showed that mice vaccinated with live BacHA or an inactive form of adjuvanted BacHA had enhanced specific antibody responses and induced protective immunity against 2009 H1N1 virus infection, suggesting the potential of baculovirus as a live or inactivated vaccine.
- Published
- 2011
- Full Text
- View/download PDF
10. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.
- Author
-
Prabakaran M, Madhan S, Prabhu N, Qiang J, and Kwang J
- Subjects
- Animals, Antibodies, Viral blood, Female, HCT116 Cells, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Hemagglutinin Glycoproteins, Influenza Virus genetics, Humans, Immunoglobulin G blood, Intestinal Mucosa immunology, Mice, Mice, Inbred BALB C, Spodoptera, Vaccination, Vaccines, Synthetic immunology, Baculoviridae genetics, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H5N1 Subtype, Influenza Vaccines immunology, Orthomyxoviridae Infections prevention & control
- Abstract
The recent outbreaks of influenza A H5N1 virus in birds and humans have necessitated the development of potent H5N1 vaccines. In this study, we evaluated the protective potential of an immediate-early promoter-based baculovirus displaying hemagglutinin (BacHA) against highly pathogenic avian influenza (HPAI) H5N1 virus infection in a mouse model. Gastrointestinal delivery of BacHA significantly enhanced the systemic immune response in terms of HA-specific serum IgG and hemagglutination inhibition (HI) titers. In addition, BacHA vaccine was able to significantly enhance the mucosal IgA level. The inclusion of recombinant cholera toxin B subunit as a mucosal adjuvant along with BacHA vaccine did not influence either the systemic or mucosal immunity. Interestingly, an inactivated form of BacHA was able to induce only a negligible level of immune responses compared to its live counterpart. Microneutralization assay also indicated that live BacHA vaccine was able to induce strong cross-clade neutralization against heterologous H5N1 strains (clade 1.0, clade 2.1, and clade 8.0) compared to the inactivated BacHA. Viral challenge studies showed that live BacHA was able to provide 100% protection against 5 50% mouse lethal doses (MLD(50)) of homologous (clade 2.1) and heterologous (clade 1) H5N1. Moreover, histopathological examinations revealed that mice vaccinated with live BacHA had only minimal bronchitis in lungs and regained their body weight more rapidly postchallenge. Furthermore, immunohistochemistry results demonstrated that the live BacHA was able to transduce and express HA in the intestinal epithelial cells in vitro and in vivo. We have demonstrated that recombinant baculovirus with a white spot syndrome virus (WSSV) immediate-early promoter 1 (ie1) acted as a vector as well as a protein vaccine and will enable the rapid production of prepandemic and pandemic vaccines without any biosafety concerns.
- Published
- 2010
- Full Text
- View/download PDF
11. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants.
- Author
-
Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, Qiang J, Meng T, Goutama M, and Kwang J
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Viral administration & dosage, Cell Line, Dogs, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Immunization, Passive, Influenza A Virus, H5N1 Subtype genetics, Lung pathology, Lung virology, Mice, Neutralization Tests, Orthomyxoviridae Infections virology, Reassortant Viruses genetics, Recombinant Fusion Proteins administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Viral therapeutic use, Influenza A Virus, H5N1 Subtype physiology, Mutation genetics, Orthomyxoviridae Infections drug therapy, Orthomyxoviridae Infections prevention & control, Recombinant Fusion Proteins therapeutic use
- Abstract
Background: Given that there is a possibility of a human H5N1 pandemic and the fact that the recent H5N1 viruses are resistant to the anti-viral drugs, newer strategies for effective therapy are warranted. Previous studies show that single mAbs in immune prophylaxis can be protective against H5N1 infection. But a single mAb may not be effective in neutralization of a broad range of different strains of H5N1 and control of potential neutralization escape mutants., Methods/principal Findings: We selected two mAbs which recognized different epitopes on the hemagglutinin molecule. These two mAbs could each neutralize in vitro escape mutants to the other and in combination could effectively neutralize viruses from clades 0, 1, 2.1, 2.2, 2.3, 4, 7 and 8 of influenza A H5N1 viruses. This combination of chimeric mAbs when administered passively, pre or post challenge with 10 MLD50 (50% mouse lethal dose) HPAI H5N1 influenza A viruses could protect 100% of the mice from two different clades of viruses (clades 1 and 2.1). We also tested the efficacy of a single dose of the combination of mAbs versus two doses. Two doses of the combination therapy not only affected early clearance of the virus from the lung but could completely prevent lung pathology of the H5N1 infected mice. No escape variants were detected after therapy., Conclusions/significance: Our studies provide proof of concept that the synergistic action of two or more mAbs in combination is required for preventing the generation of escape mutants and also to enhance the therapeutic efficacy of passive therapy against H5N1 infection. Combination therapy may allow for a lower dose of antibody to be administered for passive therapy of influenza infection and hence can be made available at reduced economic costs during an outbreak.
- Published
- 2009
- Full Text
- View/download PDF
12. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.
- Author
-
Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, and Kwang J
- Subjects
- Animals, Antibodies, Monoclonal isolation & purification, Antibodies, Viral isolation & purification, CHO Cells, Cell Fusion, Cricetinae, Cricetulus, Epitope Mapping, Lung pathology, Lung virology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections prevention & control, Protein Binding, Survival Analysis, Antibodies, Monoclonal therapeutic use, Antibodies, Viral therapeutic use, Antiviral Agents therapeutic use, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H5N1 Subtype immunology, Orthomyxoviridae Infections drug therapy
- Abstract
The HA2 glycopolypeptide (gp) is highly conserved in all influenza A virus strains, and it is known to play a major role in the fusion of the virus with the endosomal membrane in host cells during the course of viral infection. Vaccines and therapeutics targeting this HA2 gp could induce efficient broad-spectrum immunity against influenza A virus infections. So far, there have been no studies on the possible therapeutic effects of monoclonal antibodies (MAbs), specifically against the fusion peptide of hemagglutinin (HA), upon lethal infections with highly pathogenic avian influenza (HPAI) H5N1 virus. We have identified MAb 1C9, which binds to GLFGAIAGF, a part of the fusion peptide of the HA2 gp. We evaluated the efficacy of MAb 1C9 as a therapy for influenza A virus infections. This MAb, which inhibited cell fusion in vitro when administered passively, protected 100% of mice from challenge with five 50% mouse lethal doses of HPAI H5N1 influenza A viruses from two different clades. Furthermore, it caused earlier clearance of the virus from the lung. The influenza virus load was assessed in lung samples from mice challenged after pretreatment with MAb 1C9 (24 h prior to challenge) and from mice receiving early treatment (24 h after challenge). The study shows that MAb 1C9, which is specific to the antigenically conserved fusion peptide of HA2, can contribute to the cross-clade protection of mice infected with H5N1 virus and mediate more effective recovery from infection.
- Published
- 2009
- Full Text
- View/download PDF
13. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
- Author
-
Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim AP, Hanson BJ, and Kwang J
- Subjects
- Animals, Antibodies, Monoclonal immunology, Antibodies, Viral immunology, Antibodies, Viral therapeutic use, Chickens, Humans, Immunoglobulin G immunology, Immunoglobulin G therapeutic use, Immunologic Factors immunology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Premedication, Recombinant Fusion Proteins immunology, Recombinant Fusion Proteins therapeutic use, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Hemagglutinin Glycoproteins, Influenza Virus immunology, Immunization, Passive, Immunologic Factors therapeutic use, Influenza A Virus, H5N1 Subtype immunology, Orthomyxoviridae Infections therapy
- Abstract
Background: Recent outbreaks of highly pathogenic H5N1 viruses in humans indicate that no endogenous protection exists in the general population. Vaccination programmes against this new pathogen require synthesis of endogenous antibodies and cannot provide any immediate protection in the event of a pandemic. Passive immunization with humanized neutralizing monoclonal antibodies can prove to be promising in preventing a catastrophic pandemic., Methods: A murine monoclonal antibody (mAb) 3B1 of immunoglobulin M isotype was switched to a chimeric immunoglobulin G1. BALB/c mice were used to study the protective efficacy of the chimeric mAbs against a lethal H5N1 virus challenge with strains from clades 1 and 2.1. Kinetics of the viral load were determined during the course of the treatment., Results: The chimeric mAb, in passive administration, was able to protect 100% of the mice when challenged with H5N1 strains from clades 1 or 2.1. Prophylaxis at 1 day prior to challenge and treatment at 1 day after challenge with this mAb resulted in the clearance of the virus from the lungs of the infected mice within 6 days post-viral challenge., Conclusions: Passive immunotherapy using chimeric mAb 3B1 can be an effective tool in both the prophylaxis and treatment of highly pathogenic H5N1 infection, providing the immediate immunity needed to contain a future influenza pandemic.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.